{"nct_id":"NCT02485691","title":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","status":"COMPLETED","status_verified_date":"2022-05","start_date":"2015-11-09","start_date_type":"ACTUAL","primary_completion_date":"2019-03-27","primary_completion_date_type":"ACTUAL","completion_date":"2021-03-15","completion_date_type":"ACTUAL","phases":["PHASE4"],"tickers":["SNY"]}